Withdrawal from GLP-1 injections requires careful planning and medical supervision to manage the return of appetite, potential weight regain, and other physiological changes
The primary endpoints for this study were change in body weight and body composition (assessed by dual x-ray absorptiometry [DXA] scanning for total mass, fat mass, and lean mass), and we also assessed food intake, glycated hemoglobin (HbA1c%), and lipid profiles
Benefits Supports metabolic health
Feeling okay in your body only when its smaller is not the same as resilient body image
Liraglutide has been approved by the United States Food and Drug Administration (FDA) for long-term weight management (4)
According to the company's own terms of use, MEDVi states that it "does not provide any Healthcare Services through the Platform and is not licensed to practice medicine." The company further states it "does not control or interfere with the provision of Healthcare Services by the medical providers." Licensed Medical Providers are described as independent professionals contracted or employed with affiliated professional entities specifically identified on the MEDVi website as OpenLoop Health and CareGLP Affiliated P.C.s
